Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
Diabetes
Advertisement
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Perspectives in Diabetes

Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences

  1. Coen D.A. Stehouwer⇑
  1. Department of Internal Medicine and CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre+, Maastricht, the Netherlands
  1. Corresponding author: Coen D.A. Stehouwer, cda.stehouwer{at}mumc.nl.
Diabetes 2018 Sep; 67(9): 1729-1741. https://doi.org/10.2337/dbi17-0044
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

Microvascular and metabolic physiology are tightly linked. This Perspective reviews evidence that 1) the relationship between hyperglycemia and microvascular dysfunction (MVD) is bidirectional and constitutes a vicious cycle; 2) MVD in diabetes affects many, if not all, organs, which may play a role in diabetes-associated comorbidities such as depression and cognitive impairment; and 3) MVD precedes, and contributes to, hyperglycemia in type 2 diabetes (T2D) through impairment of insulin-mediated glucose disposal and, possibly, insulin secretion. Obesity and adverse early-life exposures are important drivers of MVD. MVD can be improved through weight loss (in obesity) and through exercise. Pharmacological interventions to improve MVD are an active area of investigation.

Introduction

The pathogenesis of the vascular complications of diabetes is extremely complex. The many biochemical changes induced by the diabetes milieu that are thought to be responsible for vascular damage are the subject of intense scrutiny and have been elegantly reviewed (1,2). In comparison, analysis of the initial functional and structural organ changes that provide the scaffolding for the subsequent development of complications has lagged behind (2). In this context, the aim of this Perspective is to discuss the role of microvascular dysfunction (MVD) as a central node that potentially connects the pathogenesis of type 2 diabetes (T2D) with that of diabetic microvascular complications and comorbidities, i.e., conditions that occur with greater frequency in diabetes but are not usually considered classic complications, such as (but not limited to) depression and cognitive impairment (Fig. 1).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Overview of potential roles of MVD in diabetes.

Current thinking on the microcirculation in diabetes emphasizes the role of microcirculatory damage and dysfunction in the pathogenesis of retinopathy, nephropathy, and neuropathy, collectively alluded to as “microvascular complications of diabetes.” However, these are not the only consequences of MVD. This Perspective will highlight recent insights in the role of MVD in diabetes (Fig. 1) and discuss emerging evidence that 1) subtle MVD precedes, and may predict, classic clinical features of retinopathy and nephropathy; 2) diabetic as well as prediabetic levels of hyperglycemia, in turn, are associated with subtle MVD; 3) (pre)diabetes-associated MVD is widespread and may contribute to (pre)diabetes-associated comorbidities; and 4) MVD contributes to insulin resistance and, possibly, β-cell dysfunction, and thus to hyperglycemia and onset of T2D.

Taken together, these concepts suggest that MVD and hyperglycemia may constitute a vicious cycle with widespread, multiorgan consequences. The fact that MVD (similar to atherothrombotic disease) is induced by diabetes but can occur in its absence is a potential explanation for the observation that many diseases that in part may have a microvascular origin, such as albuminuria, neuropathy, heart failure, stroke, depression, and cognitive decline, although occurring with greater frequency in diabetes, can also be seen in individuals with prediabetes or normal glucose metabolism. Thus, there may exist in T2D a “ticking clock” with regard to not only macrovascular but also microvascular disease, that is, macro- and microvascular disease processes start long before the onset of T2D.

In discussing these issues, I shall rely to an important extent on data obtained in humans, as no experimental models exist that approximate the entirety of the interconnections alluded to above. However, because many studies in humans are by necessity nonexperimental, causal inference is difficult. This is highlighted in Table 1 (2–8).

View this table:
  • View inline
  • View popup
Table 1

Causal inference in human studies on the pathogenesis of diabetes and its complications: problems, pitfalls, and potential solutions

Microvascular Function

Core functions of the microcirculation, defined as vessels with a diameter <150 µm (arterioles, capillaries and venules), are 1) to optimize the delivery of nutrients and removal of waste products in response to variations in demand (its metabolic function) and 2) to decrease and stabilize pulsatile hydrostatic pressure at the level of capillaries (its hemodynamic function). Under normal conditions, systemic, regional, and local metabolic and myogenic autoregulatory mechanisms ensure adequate progress of these microcirculatory functions (9). From the metabolic functions of the microcirculation it follows that microvascular and metabolic physiology are tightly linked. This link extends into pathophysiology so that impairments in metabolic and microvascular function often go hand in hand (10).

Indeed, microvascular endothelial cells are thought to be major targets of hyperglycemic damage because they cannot downregulate glucose transport rate when glucose concentration is elevated, resulting in intracellular hyperglycemia (1). This is thought to induce microvascular endothelial dysfunction (e.g., decreased availability of nitric oxide, increased permeability, increased leukocyte adhesion, and increased procoagulant activity) through multiple biochemical pathways (1,2) initiated by mitochondrial overproduction of reactive oxygen species (1). Other data emphasize an initiating role of impaired mitochondrial oxidative phosphorylation activity (11). Thus, metabolic dysfunction (hyperglycemia) induces MVD. However, and as discussed in detail below, MVD (specifically, decreased insulin-stimulated nitric oxide and increased insulin-stimulated endothelin production in microvascular endothelium, reduced insulin-stimulated vasomotion, and reduced capillary density) reduces insulin-mediated glucose disposal in skeletal muscle as well as insulin secretion by pancreatic islets, and so contributes to hyperglycemia (9,10).

Hyperglycemia Causes Mvd: Novel Aspects

That hyperglycemia causes microvascular disease is supported by a wealth of observational and experimental data (2) and crucially by the finding that reduction of hyperglycemia, regardless of how it is achieved, is associated with reduction of onset and progression of retinopathy and nephropathy (12–14). It should nevertheless be stressed at this point that hyperglycemia is a necessary but not a sufficient cause of the development and progression of microvascular complications of diabetes and that much work remains to be done to understand the complete causal mechanisms (Table 1) at work. Beyond this conventional concept, there is increasing evidence, discussed below, that 1) subtle MVD precedes, and may predict, common clinical features of retinopathy and nephropathy; 2) diabetic as well as prediabetic levels of hyperglycemia are associated with subtle MVD; and 3) (pre)diabetes-associated MVD is widespread and may contribute to (pre)diabetes-associated comorbidities, such as (but not limited to) depression and cognitive impairment.

Diabetic Retinopathy

Diabetic retinopathy is the classic example of hyperglycemia-induced MVD. Its first, nonproliferative stage is manifested clinically by microaneurysms (capillary wall dilation), hemorrhages (rupture), hard exudates (lipid deposits as a result of leakage), and cotton-wool spots (accumulations of axoplasmic debris related to capillary nonperfusion). So-called intraretinal microvascular abnormalities (clusters of dilated preexisting capillaries) and venous dilation and beading are also seen (15–17). An important aspect of the pathogenesis of these abnormalities involves hyperglycemia-induced dysfunction and death and insufficient renewal of arteriolar endothelial and vascular smooth muscle cells and of capillary endothelial cells and pericytes. Absent an autonomic nerve supply of the retinal microvasculature, such MVD impairs autoregulation of blood flow into retinal capillary beds, which increases capillary pressure in the retina, leading to capillary dilation, leakage, rupture, and nonperfusion (18). A clinically important development has been the elucidation of the causal role of vascular endothelial growth factor (VEGF) in diabetic macular edema and proliferative retinopathy, which are major risk factors for vision loss (15,16). The expression of VEGF by retinal endothelial cells, pericytes, and pigment epithelial cells increases in response to hypoxia, enhancing capillary permeability and stimulating angiogenesis. The efficacy of intravitreal treatment with anti-VEGF agents, such as ranibizumab and bevacizumab, is strong evidence that VEGF contributes to the pathogenesis of these features of diabetic retinopathy (15,16,19).

In both type 1 diabetes (T1D) and T2D, clinical retinopathy is preceded by subtle abnormalities of microcirculatory structure (retinal arteriolar widening [20–25], greater fractal dimension [25,26], and greater arteriolar tortuosity [25]) and function (reduced retinal arteriolar and venular dilation after flicker-light stimulation [27,28]). These subtle abnormalities may predict clinically apparent lesions (16,25,29) (Fig. 2, left panel). In general, early and otherwise uncomplicated diabetes (especially T1D but also T2D) has long been known to be associated with arteriolar widening and increased blood flow in the retina and many other organs, which, if not accompanied by venular widening, will increase capillary pressure (30) and contribute to organ damage. However, the biochemical basis, mediators responsible, differences among organs, and development over time of these phenomena remain to be clarified. In addition, arteriolar widening and increased blood flow are not constant findings (18,22,31–33). This is perhaps related in part to the co-occurrence of other risk factors that are associated with smaller diameters, such as hypertension (20), insulin resistance (9), and progression of MVD (34). Greater fractal dimension, which represents greater geometric density of the vascular branching pattern (a fractal structure because it exhibits the property of self-similarity), and greater arteriolar tortuosity (vessel undulation) have been speculated to reflect changes to improve neuroretinal perfusion (25). Arteriolar and venular dilation after flicker-light stimulation are endothelium-dependent responses, impairment of which thus signifies dysfunction of retinal microvascular endothelium (16). Although the precise mechanisms through which diabetes causes these early retinal changes are not well defined, these observations, taken together, show that subtle MVD precedes clinically manifest retinopathy. In addition, arteriolar widening (35) and impairment of arteriolar vasodilation after flicker-light stimulation (8,36) have been shown to progress linearly from normal glucose metabolism to prediabetes and T2D and to be closely associated with the level of glycemia, even in the prediabetes range. These data therefore suggest that the process that leads to clinical retinopathy starts before the onset of diabetes, at least in T2D.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

MVD and clinical manifestations in diabetic retinopathy (left) and nephropathy (right). *Prospective data are limited (see text).

Diabetic Nephropathy

Diabetic nephropathy in humans is more difficult to study than retinopathy, as noninvasive imaging is much less precise; renal biopsy, an invasive procedure, cannot be repeated on a routine basis; and accurate measurement of key physiological variables is cumbersome (glomerular filtration rate [GFR], effective renal plasma flow, and permeability of the glomerular capillary wall) or impossible (glomerular capillary pressure). Morphologically, diabetic nephropathy is characterized by arteriolar hyalinosis, glomerular basement membrane thickening, and mesangial expansion (37). Functionally, there is frequently an initial increase in GFR (hyperfiltration, usually defined as GFR >130–140 mL/min per 1.73 m2), which predisposes to and is often followed by a steady decrease of GFR over time. In parallel, urinary albumin excretion increases from normal (<30 mg/24 h) to microalbuminuria (30–300 mg/24 h) and macroalbuminuria (>300 mg/24 h) (38,39). The prevailing hypothesis is that global, whole-kidney hyperfiltration predisposes to albuminuria and decline in GFR through increased glomerular capillary pressure. Single-nephron hyperfiltration (to compensate for reduced nephron numbers) is proposed to accelerate renal function decline in later phases. An additional key mechanism that contributes to albuminuria is a primary increase in the permeability of the glomerular capillary wall.

To what extent does MVD contribute to hyperfiltration and albuminuria? The pathogenesis of hyperfiltration in diabetes is thought to have three components: structural, tubular, and microvascular (40). The structural component involves increases in kidney and nephron size and filtration surface area per glomerulus. The tubular component is characterized by enhanced proximal tubular sodium–glucose cotransport, which decreases sodium chloride delivery to the macula densa, leading to a reduction in afferent arteriolar resistance and an increase in single-nephron GFR through inhibition of tubuloglomerular feedback. The microvascular component consists of an imbalance of vasoactive factors that control pre- and postglomerular arteriolar tone, resulting in maladaptive afferent arteriolar vasodilation and efferent arteriolar constriction, not only during fasting but also postprandially (40). The pathogenesis of albuminuria, in turn, has two microvascular components. The first is an increase in glomerular capillary pressure, which itself is regulated in part at the microvascular level (see above). In accordance with this concept, interventions that reduce hyperfiltration and glomerular capillary pressure, such as with inhibitors of the renin-angiotensin system and of the sodium–glucose cotransporter type 2, rapidly reduce albuminuria (40,41), suggesting a hemodynamic mode of action. The second is through regulation of the permeability of the glomerular capillary wall (42). The glomerular filtration barrier consists of three layers: fenestrated endothelial cells covered on the luminal side by a fine meshwork of glycosaminoglycans (the endothelial glycocalyx), the glomerular basement membrane, and interdigitating podocytes. It was initially thought that the glomerular endothelial layer, due to its fenestrations, could only exclude cellular components of the blood from filtration and that podocytes acted as the ultimate barrier to flow of macromolecules into the urinary filtrate. However, in recent years it has become clear that injury to and dysfunction of any of the components of the glomerular filtration barrier, including the endothelium, can result in the development of albuminuria (42,43). In support of a role of MVD, especially of the endothelium, observational studies in humans with and without T2D have shown a continuous association between albuminuria and lower skin capillary density (44), lower heat-induced skin microvascular dilation (45), and lower flicker-light–induced retinal arteriolar dilation (45). In addition, in prospective studies, biomarkers of microvascular endothelial dysfunction and activation, such as plasma levels of von Willebrand factor and soluble adhesion molecules (sVCAM-1, sICAM-1, sE-selectin), have been shown to be strongly and independently associated with the onset and progression of microalbuminuria in people with T1D and T2D as well as in the general population (46–50). However, it is not known precisely how the dysfunction of the microvascular endothelium contributes to albuminuria in diabetes. Possibilities include impaired functioning of the endothelial glycocalyx (51) and dysfunctional paracrine cross talk between endothelial cells and podocytes. Recent experimental studies showed that, through such cross talk, endothelial dysfunction (for example, insufficient production of activated protein C [52] and DNA lesions in endothelial mitochondria [53]) can cause podocyte injury and diabetic nephropathy.

MVD contributes to both hyperfiltration and albuminuria and precedes and predicts onset of microalbuminuria (Fig. 2, right panel). In addition, hyperfiltration and albuminuria are also seen with greater frequency in individuals with prediabetes than in those with normal glucose tolerance (54,55) and are linked prospectively even in the general population (56). It therefore seems likely that, as in retinopathy, the process that leads to diabetic nephropathy starts before the onset of diabetes, at least in T2D. However, it must be recognized that advanced features of retinopathy and nephropathy are common in diabetes and rare in prediabetes. It is not clear whether this is simply a function of cumulative exposure to hyperglycemia over time or whether a threshold level of hyperglycemia is needed to produce advanced lesions.

Diabetic Nephropathy and Atherothrombotic Disease

It has long been known that albuminuria is strongly related to risk of incident atherothrombotic (i.e., large artery) disease in T1D and T2D and also in individuals without diabetes (reviewed in ref. 46). This association is independent of conventional risk factors, is proportional to the level of albuminuria, has an extremely low threshold, and is dynamic, i.e., changes in urinary albumin excretion are associated with parallel changes in cardiovascular risk (46,57–60). So what can explain this association? There is no strong evidence that (low-level) albuminuria causes atherothrombosis or that atherothrombosis causes albuminuria. Many studies have tested the hypothesis that a common risk factor (e.g., hypertension) underlies the association between albuminuria and atherothrombotic disease but, again, have found no strong evidence in favor of this contention. Against this background, the hypothesis has been advanced that generalized (large- and small-vessel) endothelial dysfunction is the common underlying pathophysiological process that explains the association between albuminuria and cardiovascular disease (46). The evidence for this hypothesis is as yet indirect, although cross-sectional studies have shown that albuminuria is independently associated with endothelial dysfunction of large arteries (46).

Interestingly, prospective studies have shown that glomerular hyperfiltration, like albuminuria, appears to be independently associated with risk of atherothrombotic disease in people with T1D or T2D and in individuals without diabetes (40,61,62). This is the more remarkable because the reference group in such studies consists of individuals with “normal” GFR, many of whom, however, are likely to have hyperfiltration at the single nephron level, thus potentially underestimating the strength of the association between hyperfiltration and atherothrombotic disease. The explanation for this association remains to be established, although there is some evidence that hyperfiltration is associated with large-artery endothelial dysfunction (63,64).

MVD and (Pre)diabetes-Associated Comorbidities

As discussed above, severe hyperglycemia, as in diabetes, can cause MVD and classic microvascular complications such as retinopathy and nephropathy, but this does not mean that MVD in diabetes is limited to the retina and kidney. MVD in diabetes in fact is a widespread phenomenon, which (as far as has been investigated) can be demonstrated in any organ in which it is measured, for example, skin, brain, heart, and lung (8,65–68). A key question is to what extent such MVD contributes to clinical disease, including the “comorbidities” so often seen in individuals with diabetes. This is an extremely important area of investigation. It should be stressed that the evidence is as yet quite limited, but it will be important to investigate, for example, whether pulmonary and coronary MVD contribute to limitations in exercise capacity and heart failure with preserved ejection fraction (67,68).

The most extensive, albeit still incomplete, evidence for a role of MVD is in cognitive impairment and depression (reviewed in refs. 69–71) (Fig. 3). On brain MRI, microvascular damage can manifest itself as white-matter hyperintensities (WMHs), cerebral microbleeds, and lacunar infarcts, collectively referred to as cerebral small-vessel disease. WMHs are structural disruptions of fiber tracts in cerebral white matter and are thought to be caused by perfusion deficits. Such lesions are accompanied by abnormal cerebral microvascular structure (arterio(lo)sclerotic changes in small arteries and arterioles) and function (impaired cerebral blood flow regulation and enhanced permeability of the blood‐brain barrier with leakage of plasma fluid components). Cerebral microvascular damage, in turn, can lead to neuronal cell death, diminished neuronal connectivity, and, ultimately, dysfunction of the brain. Brain dysfunction can manifest itself as decreased cognitive performance and as clinical cognitive impairment, including dementia. In addition, cerebral microvascular damage has been suggested to contribute to late-life depression via disruption of deep and frontal brain structures or their connecting pathways involved in mood regulation. In support of these concepts, two recent systematic reviews of prospective and cross-sectional observational data in humans have shown that cerebral small-vessel disease is consistently associated with greater risks of dementia and depression (71) and that biomarkers of MVD are associated with depression (69). Interestingly, and consistent with the hypothesis that microalbuminuria and MVD are tightly linked, we have found microalbuminuria, independent of cardiovascular risk factors, to be associated with impairment of cognitive performance (72) and depression (73) in individuals with and without T2D. Individuals with diabetes may be especially prone to cerebral MVD and its clinical consequences because of diabetes-associated large-artery stiffening (Fig. 3), as discussed further below.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Overview of the potential role of MVD in diabetes-associated cognitive impairment and late-life depression.

What of prediabetes? There are few studies on MVD in other organs than the retina and the kidney, but the association between glycemia and MVD appears not to have a threshold, at least in skin (8), retina (8), and brain (74), and is related to, and largely explained by, indices of both short- and long-term glycemia (36). Taken together, these findings support the concept that MVD in diabetes affects many organs and precedes the clinical diagnosis of T2D. MVD thus potentially contributes to comorbidities in T2D and prediabetes, although this hypothesis clearly needs to be further investigated.

Mvd Contributes To Hyperglycemia

Insulin sensitivity and β-cell function are the key determinants of glycemia. There is now solid evidence that MVD impairs insulin-mediated glucose disposal in animal models as well as in humans (75), and there is emerging evidence, mainly from experimental models, that this holds true also for β-cell function (76). Microvascular function influences insulin-mediated glucose disposal at several levels. First, to interact with its receptor on skeletal muscle cells, insulin must cross from plasma to muscle interstitium, a transendothelial transport process governed by insulin receptor–mediated signaling and nitric oxide production in microvascular endothelial cells (77). Second, access of insulin to skeletal muscle cells requires adequate capillary perfusion, i.e., a sufficient number of functioning capillary networks. Thus, capillary density is a determinant of insulin-mediated glucose disposal (78–80). Third, only ∼30% of capillaries perfusing skeletal muscle (nutritive capillary networks) are open at any given time in the resting state. Insulin can recruit previously underperfused capillaries in skeletal muscle (81) by acting as an endothelium-dependent arteriolar dilator (82). An additional mechanism to enhance capillary perfusion is by increasing vasomotion, i.e., the spontaneous rhythmic changes in arteriolar diameter that are thought to ensure optimal perfusion and nutrient delivery (83). Insulin has been shown to increase vasomotion in humans in skin and skeletal muscle (84,85), and insulin-induced changes in vasomotion and capillary recruitment are highly correlated (86,87). Impairments of these hemodynamic actions of insulin have been shown to impair insulin-mediated glucose disposal (9,77,81).

The strong correlation of insulin’s microvascular and metabolic actions, which are independent of other determinants of insulin-mediated glucose disposal such as visceral, subcutaneous, and intrahepatic fat (6), suggests coordinated behavior. For example, exercise increases human skeletal muscle insulin sensitivity via coordinated increases in microvascular perfusion and molecular signaling in muscle (80,88). In addition, mediators (such as certain adipokines) that impair insulin action in skeletal muscle in general also impair insulin action in endothelial cells (9).

Interestingly, an animal model in which insulin signal transduction is selectively impaired in endothelial cells shows not only impaired insulin-induced microvascular dilation and whole-body glucose disposal (89) but also impaired insulin secretion (90). Indeed, islet microvascular morphology is grossly abnormal in pancreata from individuals with T2D, and there is substantial experimental evidence that normal microvascular endothelial function in pancreatic islets is needed for normal glucose-induced insulin secretion (76,91). Functional studies of the islet microcirculation in humans, however, are difficult to perform given the limitations of current technologies.

The studies reviewed above show that normal microvascular function is necessary for normal insulin-mediated glucose disposal and glucose-induced insulin secretion (Fig. 4). It logically follows that MVD in individuals without diabetes should predispose to the development of T2D. We have found this indeed to be the case, regardless of how MVD was measured: per 1 SD greater impairment of microvascular function, the incidence of T2D increased by ∼25% during 2.6–12 years of follow-up (92). Thus, the association between MVD and hyperglycemia in T2D is bidirectional: hyperglycemia causes MVD and MVD precedes, and contributes to, hyperglycemia (Fig. 1). Both pathways (i.e., hyperglycemia → MVD and MVD → hyperglycemia) are characterized by impaired microvascular endothelium-dependent vasodilation. Whether hyperglycemia specifically induces the types of MVD described above that impair insulin-mediated glucose disposal in skeletal muscle as well as insulin secretion by pancreatic islets has not yet been studied, and this is an important missing link.

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

Overview of the potential role of MVD in insulin-mediated glucose disposal and β-cell function.

Obesity Is An Important Driver Of Mvd

Obesity, especially visceral obesity, is associated with MVD, including impairments in functional capillary density (93), endothelium-dependent vasodilation (93), vasomotion (94–96), and insulin-induced microvascular dilation and recruitment (93). At least some of these defects correlate with BMI and waist circumference even in the absence of obesity (96,97), supporting a continuous relationship between fat mass and microvascular function. The pathophysiological mechanisms behind the relationship between obesity and MVD are thought to be multifactorial (9).

Insulin Resistance

An important consequence of MVD in obesity is that it contributes to impairment of insulin-mediated glucose disposal (6,9). Normal insulin action in endothelial cells is to increase synthesis of nitric oxide through the PI3 kinase pathway more than endothelin synthesis through the ERK pathway, with vasodilation as the net result (98–100). Experimental evidence indicates that obesity shifts this balance toward less vasodilation, or even vasoconstriction, through adverse changes in adipokines, such as adiponectin, free fatty acids, and tumor necrosis factor-α. These changes impair insulin signal transduction in endothelial cells, resulting in less nitric oxide synthesis and/or enhanced endothelin production (101–107). In addition, a reduction in insulin-stimulated nitric oxide production in endothelial cells will impair transendothelial insulin transport (108,109). These adipokines may derive not only from visceral fat but also from subcutaneous (truncal) and perivascular fat (6,107,110).

Hypertension

A second consequence of MVD in obesity is an increase in peripheral resistance and, other things being equal, blood pressure. Hypertension is characterized by multiple abnormalities of microvascular structure and function in many organs, such as reduced density (rarefaction) of arterioles, capillaries, and venules; enhanced constriction and reduced dilation of arterioles, including reduced endothelium-dependent vasodilation induced by insulin and other mediators; decreased arteriolar diameter; and increased wall-to-lumen ratio of small arteries (remodeling). Hypertension undoubtedly causes MVD, but, as reviewed elsewhere (9,111,112), MVD is currently thought to be both cause and consequence of high blood pressure. Therefore, it is reasonable to assume that MVD can contribute to high blood pressure in obesity, although prospective studies are so far lacking. In addition, there may be a link between MVD and salt sensitivity of blood pressure, that is, a greater susceptibility to the hypertensive effects of exposure to a high salt intake. Animal models have shown that MVD in the kidney initiates and maintains salt sensitivity of blood pressure via induction of renal vasoconstriction and interstitial inflammation (113). In humans, there is a close association between skin MVD and salt sensitivity of blood pressure in normotensive and hypertensive individuals (114). Thus, MVD may also contribute to the link between obesity and salt sensitivity of blood pressure.

Hypertension, diabetes, and, to a lesser extent, obesity cause stiffening of large arteries, which impairs their cushioning function and increases pressure and flow pulsatility, which transmit distally and can damage the microcirculation (115). In the kidney, eye, and brain, the microvasculature is especially vulnerable, as it is characterized by low impedance, allowing deep penetration of the pulsatile load. In contrast, the microcirculation of other organs may be able to protect itself through effective autoregulation and/or vascular remodeling. This would dissipate most of the increased pulsatile energy by arteries and large arterioles proximal to capillary beds and thus limit penetration of the pulsatile load. Indeed, arterial stiffening is associated with MVD in kidney (116), eye (117), and brain (118) but not, for example, in skin (119). This may be one reason why, in diabetes and hypertension, the eye, kidney, and brain (Fig. 3) are more often affected by microvascular disease than are other organs.

MVD in Adipose Tissue

A hypothesis has been advanced that MVD of adipose tissue is a primary cause of adipose tissue dysfunction, resulting in adverse changes in adipokines (120). In animal models, nutrient overload causes adipose tissue microvascular endothelium to activate pathways that initiate adipose tissue inflammation even before weight gain and overt obesity (120). In addition, an intervention that specifically targeted the microcirculation in adipose tissue prevented obesity and related metabolic complications (121). Although clearly of interest, these concepts have yet to be tested in humans.

Early-Life Exposures And Mvd

Epidemiological studies have consistently demonstrated that low weight at birth is associated with adverse cardiovascular and metabolic outcomes in later life, especially when combined with accelerated postnatal (catch-up) growth and later obesity (122). In this context, it is noteworthy that both antenatal and postnatal early-life exposures are associated with microvascular function, specifically capillary density and microvascular endothelium-dependent vasodilation. For example, in otherwise healthy individuals born at term, low birth weight was associated with MVD both in adults (123) and in prepubertal children (124). In healthy newborns, smaller size at birth (125), maternal hypertension (125), and rapid growth in the first month (126) were associated with MVD. The latter observation suggests that the early postnatal period may provide a window of opportunity for prevention of MVD.

Thus, low birth weight, rapid early growth, obesity, and hypertension are all associated with MVD, and the adverse cardiometabolic outcomes associated with low birth weight are enhanced by catch-up growth and obesity. This suggests a scenario in which MVD may play a central role as a prime target of risk factors, including adverse early-life conditions, and as a mediator in the pathway between adverse early-life conditions and hypertension, T2D, and cardiovascular disease. This sequence of events could then plausibly be aggravated by obesity, which itself contributes to MVD.

The above relates mainly to T2D. However, there is no reason why the vicious cycle between hyperglycemia and MVD could not occur in T1D. If T1D develops in adulthood, common risk factors (obesity, physical inactivity, hypertension, and early-life exposures) can be present that may aggravate hyperglycemia-associated MVD. If T1D develops in childhood, such effects may initially be largely absent but could occur later. Indeed, the onset and severity of microvascular complications in T1D are known to be modulated by variables other than the severity of hyperglycemia, such as hypertension, obesity, and physical inactivity (2). Whether this is mediated by MVD is not known but is a testable hypothesis.

Interventions To Improve Microvascular Function

As discussed in more detail below, there is good evidence that lifestyle can improve MVD in humans. In addition, some established pharmacological interventions may act in part through improving MVD. Recently, specific treatments to improve MVD have also come under investigation, but data in humans are as yet relatively limited (127).

Lifestyle Factors

MVD in obesity appears at least partly reversible through weight loss. In abdominally obese men, diet-induced weight loss (∼10 kg in 8 weeks), as compared with a weight-maintenance diet, improved insulin-induced microvascular recruitment in skeletal muscle (6) and normalized the retinal arteriole-to-venule ratio (128). Controlled data on whether specific nutritional interventions can improve MVD are very limited (129). In contrast, exercise has clearly been shown to improve insulin-induced microvascular recruitment and capillary density in skeletal muscle (80,88). In the Look AHEAD (Action for Health in Diabetes) trial in T2D, an intensive lifestyle intervention through weight loss and exercise was associated with improvement of the renal outcome (both albuminuria and estimated GFR [130]), depression (131), and brain WMHs (132) but not cognitive performance (132,133). To what extent such improvements are mediated by amelioration of MVD remains to be studied.

Pharmacological Interventions

Angiotensin II is thought to impair insulin-mediated microvascular dilation through increasing the production of reactive oxygen species (134). Conversely, blocking its action improves insulin-induced microvascular function (135,136), which may contribute to the antidiabetogenic actions of angiotensin receptor blockers and ACE inhibitors (137). Blocking the vascular actions of aldosterone through the mineralocorticoid receptor may also be a promising target. A recent well-controlled study showed that mineralocorticoid receptor blockade improves coronary microvascular function in individuals with T2D (138).

Treatment of hyperglycemia in diabetes reduces microvascular complications (12–14). An important issue is whether interventions in individuals with less severe hyperglycemia might also be effective. In this context, a recent study suggested that intervention in individuals with prediabetes may reduce microvascular disease (139). An additional important question is whether clarification of the biochemical pathways through which hyperglycemia acts to damage endothelial cells (1,2,11) will allow specific treatments to be developed. For example, hyperglycemia and obesity (to a lesser extent) increase dicarbonyl stress with increased formation of methylglyoxal, and this may be one important pathway through which hyperglycemia exerts its deleterious effects. Methylglyoxal is a highly potent glycating agent of protein that forms the major advanced glycation end product, hydroimidazolone MG-H1, which leads to protein inactivation and cellular dysfunction. Methylglyoxal has also been shown to impair the action of insulin on the endothelium both in vitro and in vivo (140). Its levels can be reduced in at least two ways that do not depend on the level of glycemia, namely by increasing the activity of glyoxalase 1, the enzyme that converts methylglyoxal to d-lactate, and by pyridoxamine, a naturally occurring vitamin B6 vitamer that is thought to act by trapping and inactivating methylglyoxal. Both an intervention that induces glyoxalase 1 and treatment with pyridoxamine are associated with improved vascular and metabolic function (141,142).

Some antihyperglycemia agents may improve MVD at least in part through nonglucose pathways. For example, as compared with placebo, long-term treatment with metformin in insulin-treated T2D individuals was associated with a reduction in plasma levels of biomarkers of MVD in a way not explained by differences in glycemia, and this reduction was associated with improved cardiovascular outcomes (143). Recent novel treatments also suggest a role for effects on microvascular function. Notably, glucagon-like peptide 1 receptor agonists may improve endothelial function in arterioles through an AMPK-dependent pathway (144,145) and are also associated with improved recruitment of skeletal muscle and cardiac microvasculature (146,147). Recent outcome trials have shown that glucagon-like peptide 1 receptor agonists can improve renal outcomes in T2D in a way not clearly explained by improved glycemic control (148), but their effects on retinopathy need further clarification (149). Finally, treatment with inhibitors of the sodium–glucose cotransporter type 2 in the renal proximal tubule can also improve renal outcomes (41,150), possibly by restoring tubuloglomerular feedback and reversing inappropriate renal afferent arteriolar dilation (41).

Conclusions

Microvascular and metabolic physiology are tightly linked. Hyperglycemia causes MVD and microvascular disease, but the relationship between hyperglycemia and MVD is bidirectional and constitutes a vicious cycle. MVD in diabetes affects many, if not all, organs, which may play a role in diabetes-associated comorbidities such as depression and cognitive impairment. MVD precedes, and contributes to, hyperglycemia in T2D through impairment of insulin-mediated glucose disposal and, possibly, insulin secretion. Obesity and adverse early-life exposures are important drivers of MVD. MVD can be improved through weight loss (in obesity) and through exercise. Pharmacological interventions to improve MVD are an active area of investigation.

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

  • Received January 8, 2018.
  • Accepted June 18, 2018.
  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Brownlee M
    . The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–1625pmid:15919781
    OpenUrlFREE Full Text
  2. ↵
    1. Forbes JM,
    2. Cooper ME
    . Mechanisms of diabetic complications. Physiol Rev 2013;93:137–188pmid:23303908
    OpenUrlCrossRefPubMed
    1. Rothman KJ,
    2. Greenland S
    1. Rothman KJ,
    2. Greenland S
    . Causation and causal inference. In Modern Epidemiology. 2nd ed. Rothman KJ, Greenland S, Eds. Philadelphia, Lippincott-Raven Publishers, 1998, p. 7–28
    1. Lachin JM,
    2. Genuth S,
    3. Nathan DM,
    4. Zinman B,
    5. Rutledge BN; DCCT/EDIC Research Group
    . Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial--revisited. Diabetes 2008;57:995–1001pmid:18223010
    OpenUrlAbstract/FREE Full Text
    1. Brownlee M,
    2. Hirsch IB
    . Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707–1708pmid:16609094
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Kusters YH,
    2. Schalkwijk CG,
    3. Houben AJ, et al
    . Independent tissue contributors to obesity-associated insulin resistance. JCI Insight 2017;2:e89695pmid:28679946
    OpenUrlPubMed
    1. Katusic ZS,
    2. Austin SA
    . Endothelial nitric oxide: protector of a healthy mind. Eur Heart J 2014;35:888–894pmid:24357508
    OpenUrlCrossRefPubMed
  4. ↵
    1. Sörensen BM,
    2. Houben AJHM,
    3. Berendschot TTJM, et al
    . Prediabetes and type 2 diabetes are associated with generalized microvascular dysfunction: The Maastricht Study. Circulation 2016;134:1339–1352pmid:27678264
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Jonk AM,
    2. Houben AJHM,
    3. de Jongh RT,
    4. Serné EH,
    5. Schaper NC,
    6. Stehouwer CDA
    . Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology (Bethesda) 2007;22:252–260pmid:17699878
    OpenUrlCrossRefPubMed
  6. ↵
    1. Stehouwer CDA
    . The metabolic-microvascular dysregulation syndrome. Artery Res 2018;21:78–83
    OpenUrl
  7. ↵
    1. Sharma K
    . Mitochondrial hormesis and diabetic complications. Diabetes 2015;64:663–672pmid:25713188
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Nathan DM,
    2. Genuth S,
    3. Lachin J, et al.; Diabetes Control and Complications Trial Research Group
    . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986pmid:8366922
    OpenUrlCrossRefPubMedWeb of Science
    1. UK Prospective Diabetes Study (UKPDS) Group
    . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853pmid:9742976
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Zoungas S,
    2. Arima H,
    3. Gerstein HC, et al.; Collaborators on Trials of Lowering Glucose (CONTROL) group
    . Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:431–437pmid:28365411
    OpenUrlCrossRefPubMed
  10. ↵
    1. Antonetti DA,
    2. Klein R,
    3. Gardner TW
    . Diabetic retinopathy. N Engl J Med 2012;366:1227–1239pmid:22455417
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Cheung N,
    2. Mitchell P,
    3. Wong TY
    . Diabetic retinopathy. Lancet 2010;376:124–136pmid:20580421
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Hammes HP
    . Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia 2018;61:29–38pmid:28942458
    OpenUrlPubMed
  13. ↵
    1. Gardiner TA,
    2. Archer DB,
    3. Curtis TM,
    4. Stitt AW
    . Arteriolar involvement in the microvascular lesions of diabetic retinopathy: implications for pathogenesis. Microcirculation 2007;14:25–38pmid:17365659
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Elman MJ,
    2. Aiello LP,
    3. Beck RW, et al.; Diabetic Retinopathy Clinical Research Network
    . Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064–1077.e35pmid:20427088
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Wong TY,
    2. Islam FM,
    3. Klein R, et al
    . Retinal vascular caliber, cardiovascular risk factors, and inflammation: the Multi-Ethnic Study of Atherosclerosis (MESA). Invest Ophthalmol Vis Sci 2006;47:2341–2350pmid:16723443
    OpenUrlAbstract/FREE Full Text
    1. Tikellis G,
    2. Wang JJ,
    3. Tapp R, et al
    . The relationship of retinal vascular calibre to diabetes and retinopathy: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetologia 2007;50:2263–2271pmid:17891374
    OpenUrlCrossRefPubMed
  16. ↵
    1. Rogers SL,
    2. Tikellis G,
    3. Cheung N, et al
    . Retinal arteriolar caliber predicts incident retinopathy: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes Care 2008;31:761–763pmid:18184895
    OpenUrlAbstract/FREE Full Text
    1. Cheung N,
    2. Rogers SL,
    3. Donaghue KC,
    4. Jenkins AJ,
    5. Tikellis G,
    6. Wong TY
    . Retinal arteriolar dilation predicts retinopathy in adolescents with type 1 diabetes. Diabetes Care 2008;31:1842–1846pmid:18523143
    OpenUrlAbstract/FREE Full Text
    1. Islam FM,
    2. Nguyen TT,
    3. Wang JJ, et al
    . Quantitative retinal vascular calibre changes in diabetes and retinopathy: the Singapore Malay eye study. Eye (Lond) 2009;23:1719–1724pmid:19079148
    OpenUrlPubMed
  17. ↵
    1. Cheung CY,
    2. Sabanayagam C,
    3. Law AK, et al
    . Retinal vascular geometry and 6 year incidence and progression of diabetic retinopathy. Diabetologia 2017;60:1770–1781pmid:28623387
    OpenUrlPubMed
  18. ↵
    1. Cheung N,
    2. Donaghue KC,
    3. Liew G, et al
    . Quantitative assessment of early diabetic retinopathy using fractal analysis. Diabetes Care 2009;32:106–110pmid:18835945
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Mandecka A,
    2. Dawczynski J,
    3. Blum M, et al
    . Influence of flickering light on the retinal vessels in diabetic patients. Diabetes Care 2007;30:3048–3052pmid:17728481
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Nguyen TT,
    2. Kawasaki R,
    3. Wang JJ, et al
    . Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy. Diabetes Care 2009;32:2075–2080pmid:19641162
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Cheung CY,
    2. Ikram MK,
    3. Klein R,
    4. Wong TY
    . The clinical implications of recent studies on the structure and function of the retinal microvasculature in diabetes. Diabetologia 2015;58:871–885pmid:25669631
    OpenUrlCrossRefPubMed
  22. ↵
    1. Stehouwer CD,
    2. Schaper NC
    . The pathogenesis of vascular complications of diabetes mellitus: one voice or many? Eur J Clin Invest 1996;26:535–543pmid:8864414
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Klein R,
    2. Klein BE,
    3. Moss SE, et al.; The Wisconsin Epidemiologic Study of Diabetic Retinopathy
    . The relation of retinal vessel caliber to the incidence and progression of diabetic retinopathy: XIX: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol 2004;122:76–83pmid:14718299
    OpenUrlCrossRefPubMedWeb of Science
    1. Klein R,
    2. Klein BE,
    3. Moss SE,
    4. Wong TY,
    5. Sharrett AR
    . Retinal vascular caliber in persons with type 2 diabetes: the Wisconsin Epidemiological Study of Diabetic Retinopathy: XX. Ophthalmology 2006;113:1488–1498pmid:16828517
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Klein R,
    2. Klein BE,
    3. Moss SE,
    4. Wong TY; The Wisconsin Epidemiologic Study of Diabetic Retinopathy
    . Retinal vessel caliber and microvascular and macrovascular disease in type 2 diabetes: XXI: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2007;114:1884–1892pmid:17540447
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Benitez-Aguirre PZ,
    2. Wong TY,
    3. Craig ME, et al.; Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT)
    . The Adolescent Cardio-Renal Intervention Trial (AdDIT): retinal vascular geometry and renal function in adolescents with type 1 diabetes. Diabetologia 2018;61:968–976pmid:29396691
    OpenUrlPubMed
  26. ↵
    1. Nguyen TT,
    2. Wang JJ,
    3. Sharrett AR, et al
    . Relationship of retinal vascular caliber with diabetes and retinopathy: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2008;31:544–549pmid:18070990
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Sörensen BM,
    2. Houben AJHM,
    3. Berendschot TTJM, et al
    . Hyperglycemia is the main mediator of prediabetes- and type 2 diabetes-associated impairment of microvascular function: The Maastricht Study. Diabetes Care 2017;40:e103–e105pmid:28626010
    OpenUrlFREE Full Text
  28. ↵
    1. Fioretto P,
    2. Mauer M
    . Histopathology of diabetic nephropathy. Semin Nephrol 2007;27:195–207pmid:17418688
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Mogensen CE
    . Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes 1990;39:761–767pmid:2191882
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Mogensen CE
    . Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999;42:263–285pmid:10096778
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Tonneijck L,
    2. Muskiet MH,
    3. Smits MM, et al
    . Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 2017;28:1023–1039pmid:28143897
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Cherney DZI,
    2. Zinman B,
    3. Inzucchi SE, et al
    . Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017;5:610–621pmid:28666775
    OpenUrlPubMed
  33. ↵
    1. Schlöndorff D,
    2. Wyatt CM,
    3. Campbell KN
    . Revisiting the determinants of the glomerular filtration barrier: what goes round must come round. Kidney Int 2017;92:533–536pmid:28807257
    OpenUrlPubMed
  34. ↵
    1. Buelli S,
    2. Perico L,
    3. Benigni A
    . Untangling the knot in diabetic nephropathy: the unanticipated role of glycocalyx in the antiproteinuric effect of endothelin receptor antagonists. Diabetes 2016;65:2115–2117pmid:27456616
    OpenUrlFREE Full Text
  35. ↵
    1. Martens RJH,
    2. Henry RMA,
    3. Houben AJHM, et al
    . Capillary rarefaction associates with albuminuria: The Maastricht Study. J Am Soc Nephrol 2016;27:3748–3757pmid:27160406
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Martens RJH,
    2. Houben AJHM,
    3. Kooman JP, et al
    . Microvascular endothelial dysfunction is associated with albuminuria: The Maastricht Study. J Hypertens 2018;36:1178–1187pmid:29373478
    OpenUrlPubMed
  37. ↵
    1. Stehouwer CDA,
    2. Smulders YM
    . Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 2006;17:2106–2111pmid:16825333
    OpenUrlAbstract/FREE Full Text
    1. Stehouwer CDA,
    2. Stroes ESG,
    3. Hackeng WHL,
    4. Mulder PGH,
    5. den Ottolander GJH
    . Von Willebrand Factor and development of diabetic nephropathy in insulin-dependent diabetes mellitus [published correction appears in Diabetes 1991;40:1746]. Diabetes 1991;40:971–976pmid:1907250
    OpenUrlAbstract/FREE Full Text
    1. Stehouwer CDA,
    2. Nauta JJP,
    3. Zeldenrust GC,
    4. Hackeng WHL,
    5. Donker AJM,
    6. den Ottolander GJH
    . Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992;340:319–323pmid:1353802
    OpenUrlCrossRefPubMedWeb of Science
    1. Stehouwer CDA,
    2. Fischer HRA,
    3. van Kuijk AWR,
    4. Polak BCP,
    5. Donker AJM
    . Endothelial dysfunction precedes the development of microalbuminuria in insulin-dependent diabetes mellitus. Diabetes 1995;44:561–564pmid:7729616
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Stehouwer CDA,
    2. Gall MA,
    3. Twisk JWR,
    4. Knudsen E,
    5. Emeis JJ,
    6. Parving HH
    . Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157–1165pmid:11916939
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Nieuwdorp M,
    2. Mooij HL,
    3. Kroon J, et al
    . Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006;55:1127–1132pmid:16567538
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Siddiqi FS,
    2. Advani A
    . Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes. Diabetes 2013;62:3647–3655pmid:24158990
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Qi H,
    2. Casalena G,
    3. Shi S, et al
    . Glomerular endothelial mitochondrial dysfunction is essential and characteristic of diabetic kidney disease susceptibility. Diabetes 2017;66:763–778pmid:27899487
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Melsom T,
    2. Mathisen UD,
    3. Ingebretsen OC, et al
    . Impaired fasting glucose is associated with renal hyperfiltration in the general population. Diabetes Care 2011;34:1546–1551pmid:21593291
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Melsom T,
    2. Schei J,
    3. Stefansson VT, et al
    . Prediabetes and risk of glomerular hyperfiltration and albuminuria in the general nondiabetic population: a prospective cohort study. Am J Kidney Dis 2016;67:841–850pmid:26744126
    OpenUrlCrossRefPubMed
  44. ↵
    1. Melsom T,
    2. Stefansson V,
    3. Schei J, et al
    . Association of increasing GFR with change in albuminuria in the general population. Clin J Am Soc Nephrol 2016;11:2186–2194pmid:27683625
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Mogensen CE
    . Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356–360pmid:6690964
    OpenUrlCrossRefPubMedWeb of Science
    1. Rossing P,
    2. Hougaard P,
    3. Borch-Johnsen K,
    4. Parving HH
    . Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996;313:779–784pmid:8842069
    OpenUrlAbstract/FREE Full Text
    1. Damsgaard EM,
    2. Frøland A,
    3. Jørgensen OD,
    4. Mogensen CE
    . Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 1992;41:731–735pmid:1513094
    OpenUrlPubMedWeb of Science
  46. ↵
    1. Beijers HJ,
    2. Ferreira I,
    3. Bravenboer B, et al
    . Microalbuminuria and cardiovascular autonomic dysfunction are independently associated with cardiovascular mortality: evidence for distinct pathways: the Hoorn Study. Diabetes Care 2009;32:1698–1703pmid:19564456
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Nitsch D,
    2. Grams M,
    3. Sang Y, et al.; Chronic Kidney Disease Prognosis Consortium
    . Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013;346:f324pmid:23360717
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Reboldi G,
    2. Verdecchia P,
    3. Fiorucci G, et al
    . Glomerular hyperfiltration is a predictor of adverse cardiovascular outcomes. Kidney Int 2018;93:195–203pmid:28935213
    OpenUrlPubMed
  49. ↵
    1. Cherney DZ,
    2. Miller JA,
    3. Scholey JW, et al
    . Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes. Diabetes Care 2010;33:1344–1346pmid:20332349
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Cherney DZ,
    2. Reich HN,
    3. Jiang S, et al
    . Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 2012;303:R710–R718pmid:22855276
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    1. von Scholten BJ,
    2. Hasbak P,
    3. Christensen TE, et al
    . Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. Diabetologia 2016;59:371–378pmid:26526662
    OpenUrlCrossRefPubMed
    1. Weinstein G,
    2. Maillard P,
    3. Himali JJ, et al
    . Glucose indices are associated with cognitive and structural brain measures in young adults. Neurology 2015;84:2329–2337pmid:25948725
    OpenUrlPubMed
  52. ↵
    1. Roberts TJ,
    2. Burns AT,
    3. MacIsaac RJ,
    4. MacIsaac AI,
    5. Prior DL,
    6. La Gerche A
    . Diagnosis and significance of pulmonary microvascular disease in diabetes. Diabetes Care 2018;41:854–861pmid:29351959
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Taqueti VR,
    2. Solomon SD,
    3. Shah AM, et al
    . Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018;39:840–849pmid:29293969
    OpenUrlPubMed
  54. ↵
    1. van Agtmaal MJM,
    2. Houben AJHM,
    3. Pouwer F,
    4. Stehouwer CDA,
    5. Schram MT
    . Association of microvascular dysfunction with late-life depression: a systematic review and meta-analysis. JAMA Psychiatry 2017;74:729–739pmid:28564681
    OpenUrlPubMed
    1. van Sloten TT,
    2. Protogerou AD,
    3. Henry RM,
    4. Schram MT,
    5. Launer LJ,
    6. Stehouwer CD
    . Association between arterial stiffness, cerebral small vessel disease and cognitive impairment: A systematic review and meta-analysis. Neurosci Biobehav Rev 2015;53:121–130pmid:25827412
    OpenUrlCrossRefPubMed
  55. ↵
    1. Rensma SP,
    2. van Sloten TT,
    3. Launer LJ,
    4. Stehouwer CDA
    . Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis. Neurosci Biobehav Rev 2018;90:164–173pmid:29656031
    OpenUrlPubMed
  56. ↵
    1. Martens RJ,
    2. Kooman JP,
    3. Stehouwer CD, et al
    . Estimated GFR, albuminuria, and cognitive performance: The Maastricht Study. Am J Kidney Dis 2017;69:179–191pmid:27291486
    OpenUrlCrossRefPubMed
  57. ↵
    1. Martens RJH,
    2. Kooman JP,
    3. Stehouwer CDA, et al
    . Albuminuria is associated with a higher prevalence of depression in a population-based cohort study: The Maastricht Study. Nephrol Dial Transplant 2018;33:128–138pmid:27965374
    OpenUrlPubMed
  58. ↵
    1. Reitz C,
    2. Guzman VA,
    3. Narkhede A,
    4. DeCarli C,
    5. Brickman AM,
    6. Luchsinger JA
    . Relation of dysglycemia to structural brain changes in a multiethnic elderly cohort. J Am Geriatr Soc 2017;65:277–285pmid:27917464
    OpenUrlPubMed
  59. ↵
    1. Muris DMJ,
    2. Houben AJHM,
    3. Schram MT,
    4. Stehouwer CDA
    . Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance. Rev Endocr Metab Disord 2013;14:29–38pmid:23299657
    OpenUrlCrossRefPubMed
  60. ↵
    1. Hogan MF,
    2. Hull RL
    . The islet endothelial cell: a novel contributor to beta cell secretory dysfunction in diabetes. Diabetologia 2017;60:952–959pmid:28396983
    OpenUrlPubMed
  61. ↵
    1. Barrett EJ,
    2. Eringa EC
    . The vascular contribution to insulin resistance: promise, proof, and pitfalls. Diabetes 2012;61:3063–3065pmid:23172953
    OpenUrlFREE Full Text
  62. ↵
    1. Lillioja S,
    2. Young AA,
    3. Culter CL, et al
    . Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987;80:415–424pmid:3301899
    OpenUrlCrossRefPubMedWeb of Science
    1. Serné EH,
    2. Stehouwer CDA,
    3. ter Maaten JC, et al
    . Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 1999;99:896–902pmid:10027812
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Sjøberg KA,
    2. Frøsig C,
    3. Kjøbsted R, et al
    . Exercise increases human skeletal muscle insulin sensitivity via coordinated increases in microvascular perfusion and molecular signaling. Diabetes 2017;66:1501–1510pmid:28292969
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Clark MG,
    2. Wallis MG,
    3. Barrett EJ, et al
    . Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol Endocrinol Metab 2003;284:E241–E258pmid:12531739
    OpenUrlCrossRefPubMedWeb of Science
  65. ↵
    1. Laakso M,
    2. Edelman SV,
    3. Brechtel G,
    4. Baron AD
    . Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990;85:1844–1852pmid:2189893
    OpenUrlCrossRefPubMedWeb of Science
  66. ↵
    1. Pradhan RK,
    2. Chakravarthy VS
    . Informational dynamics of vasomotion in microvascular networks: a review. Acta Physiol (Oxf) 2011;201:193–218pmid:20887358
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Serné EH,
    2. IJzerman RG,
    3. Gans ROB, et al
    . Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes 2002;51:1515–1522pmid:11978650
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. de Jongh RT,
    2. Clark ADH,
    3. IJzerman RG,
    4. Serné EH,
    5. de Vries G,
    6. Stehouwer CDA
    . Physiological hyperinsulinaemia increases intramuscular microvascular reactive hyperaemia and vasomotion in healthy volunteers. Diabetologia 2004;47:978–986pmid:15168017
    OpenUrlPubMed
  69. ↵
    1. Newman JM,
    2. Dwyer RM,
    3. St-Pierre P,
    4. Richards SM,
    5. Clark MG,
    6. Rattigan S
    . Decreased microvascular vasomotion and myogenic response in rat skeletal muscle in association with acute insulin resistance. J Physiol 2009;587:2579–2588pmid:19403615
    OpenUrlCrossRefPubMed
  70. ↵
    1. de Boer MP,
    2. Meijer RI,
    3. Newman J, et al
    . Insulin-induced changes in microvascular vasomotion and capillary recruitment are associated in humans. Microcirculation 2014;21:380–387pmid:24444138
    OpenUrlCrossRefPubMed
  71. ↵
    1. Prior SJ,
    2. Goldberg AP,
    3. Ortmeyer HK, et al
    . Increased skeletal muscle capillarization independently enhances insulin sensitivity in older adults after exercise training and detraining. Diabetes 2015;64:3386–3395pmid:26068543
    OpenUrlAbstract/FREE Full Text
  72. ↵
    1. Kubota T,
    2. Kubota N,
    3. Kumagai H, et al
    . Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011;13:294–307pmid:21356519
    OpenUrlCrossRefPubMedWeb of Science
  73. ↵
    1. Hashimoto S,
    2. Kubota N,
    3. Sato H, et al
    . Insulin receptor substrate-2 (Irs2) in endothelial cells plays a crucial role in insulin secretion. Diabetes 2015;64:876–886pmid:25277391
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Carlsson PO,
    2. Jansson L
    . Disruption of insulin receptor signaling in endothelial cells shows the central role of an intact islet blood flow for in vivo β-cell function. Diabetes 2015;64:700–702pmid:25713194
    OpenUrlFREE Full Text
  75. ↵
    1. Muris DMJ,
    2. Houben AJHM,
    3. Schram MT,
    4. Stehouwer CDA
    . Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2012;32:3082–3094pmid:23042819
    OpenUrlAbstract/FREE Full Text
  76. ↵
    1. de Jongh RT,
    2. Serné EH,
    3. IJzerman RG,
    4. de Vries G,
    5. Stehouwer CDA
    . Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004;109:2529–2535pmid:15136505
    OpenUrlAbstract/FREE Full Text
  77. ↵
    1. de Jongh RT,
    2. Serné EH,
    3. IJzerman RG,
    4. Jørstad HT,
    5. Stehouwer CDA
    . Impaired local microvascular vasodilatory effects of insulin and reduced skin microvascular vasomotion in obese women. Microvasc Res 2008;75:256–262pmid:17920639
    OpenUrlCrossRefPubMed
    1. Jonk AM,
    2. Houben AJ,
    3. Schaper NC, et al
    . Meal-related increases in microvascular vasomotion are impaired in obese individuals: a potential mechanism in the pathogenesis of obesity-related insulin resistance. Diabetes Care 2011;34(Suppl. 2):S342–S348pmid:21525480
    OpenUrlFREE Full Text
  78. ↵
    1. Muris DMJ,
    2. Houben AJHM,
    3. Kroon AA, et al
    . Age, waist circumference, and blood pressure are associated with skin microvascular flow motion: The Maastricht Study. J Hypertens 2014;32:2439–2449; discussion 2449pmid:25222377
    OpenUrlCrossRefPubMed
  79. ↵
    1. de Jongh RT,
    2. IJzerman RG,
    3. Serné EH, et al
    . Visceral and truncal subcutaneous adipose tissue are associated with impaired capillary recruitment in healthy individuals. J Clin Endocrinol Metab 2006;91:5100–5106pmid:17003093
    OpenUrlCrossRefPubMedWeb of Science
  80. ↵
    1. Zeng G,
    2. Quon MJ
    . Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;98:894–898pmid:8770859
    OpenUrlCrossRefPubMedWeb of Science
    1. Cardillo C,
    2. Nambi SS,
    3. Kilcoyne CM, et al
    . Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 1999;100:820–825pmid:10458717
    OpenUrlAbstract/FREE Full Text
  81. ↵
    1. Vicent D,
    2. Ilany J,
    3. Kondo T, et al
    . The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 2003;111:1373–1380pmid:12727929
    OpenUrlCrossRefPubMedWeb of Science
  82. ↵
    1. Eringa EC,
    2. Stehouwer CDA,
    3. Merlijn T,
    4. Westerhof N,
    5. Sipkema P
    . Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc Res 2002;56:464–471pmid:12445887
    OpenUrlCrossRefPubMedWeb of Science
    1. Eringa EC,
    2. Stehouwer CDA,
    3. van Nieuw Amerongen GP,
    4. Ouwehand L,
    5. Westerhof N,
    6. Sipkema P
    . Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am J Physiol Heart Circ Physiol 2004;287:H2043–H2048pmid:15059773
    OpenUrlCrossRefPubMedWeb of Science
    1. de Jongh RT,
    2. Serné EH,
    3. IJzerman RG,
    4. de Vries G,
    5. Stehouwer CDA
    . Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes 2004;53:2873–2882pmid:15504968
    OpenUrlAbstract/FREE Full Text
    1. Eringa EC,
    2. Stehouwer CDA,
    3. Walburg K, et al
    . Physiological concentrations of insulin induce endothelin-dependent vasoconstriction of skeletal muscle resistance arteries in the presence of tumor necrosis factor-α dependence on c-Jun N-terminal kinase. Arterioscler Thromb Vasc Biol 2006;26:274–280pmid:16322532
    OpenUrlAbstract/FREE Full Text
    1. Eringa EC,
    2. Stehouwer CDA,
    3. Roos MH,
    4. Westerhof N,
    5. Sipkema P
    . Selective resistance to vasoactive effects of insulin in muscle resistance arteries of obese Zucker (fa/fa) rats. Am J Physiol Endocrinol Metab 2007;293:E1134–E1139pmid:17623751
    OpenUrlCrossRefPubMedWeb of Science
    1. Bakker W,
    2. Sipkema P,
    3. Stehouwer CDA, et al
    . Protein kinase C theta activation induces insulin-mediated constriction of muscle resistance arteries. Diabetes 2008;57:706–713pmid:18086904
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Meijer RI,
    2. Bakker W,
    3. Alta CL, et al
    . Perivascular adipose tissue control of insulin-induced vasoreactivity in muscle is impaired in db/db mice. Diabetes 2013;62:590–598pmid:23048187
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Barrett EJ,
    2. Liu Z
    . The endothelial cell: an “early responder” in the development of insulin resistance. Rev Endocr Metab Disord 2013;14:21–27pmid:23306779
    OpenUrlCrossRefPubMed
  85. ↵
    1. Tanigaki K,
    2. Chambliss KL,
    3. Yuhanna IS, et al
    . Endothelial Fcγ receptor IIB activation blunts insulin delivery to skeletal muscle to cause insulin resistance in mice. Diabetes 2016;65:1996–2005pmid:27207525
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Yudkin JS,
    2. Eringa E,
    3. Stehouwer CDA
    . “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005;365:1817–1820pmid:15910955
    OpenUrlCrossRefPubMedWeb of Science
  87. ↵
    1. Levy BI,
    2. Ambrosio G,
    3. Pries AR,
    4. Struijker-Boudier HA
    . Microcirculation in hypertension: a new target for treatment? Circulation 2001;104:735–740pmid:11489784
    OpenUrlFREE Full Text
  88. ↵
    1. Serné EH,
    2. de Jongh RT,
    3. Eringa EC,
    4. IJzerman RG,
    5. Stehouwer CDA
    . Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007;50:204–211pmid:17470716
    OpenUrlFREE Full Text
  89. ↵
    1. Johnson RJ,
    2. Herrera-Acosta J,
    3. Schreiner GF,
    4. Rodriguez-Iturbe B
    . Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002;346:913–923pmid:11907292
    OpenUrlCrossRefPubMedWeb of Science
  90. ↵
    1. de Jongh RT,
    2. Serné EH,
    3. IJzerman RG,
    4. Stehouwer CDA
    . Microvascular function: a potential link between salt sensitivity, insulin resistance and hypertension. J Hypertens 2007;25:1887–1893pmid:17762653
    OpenUrlCrossRefPubMedWeb of Science
  91. ↵
    1. Stehouwer CDA,
    2. Henry RMA,
    3. Ferreira I
    . Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008;51:527–539pmid:18239908
    OpenUrlCrossRefPubMedWeb of Science
  92. ↵
    1. Hermans MMH,
    2. Henry R,
    3. Dekker JM, et al
    . Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol 2007;18:1942–1952pmid:17460143
    OpenUrlAbstract/FREE Full Text
  93. ↵
    1. Cheung N,
    2. Sharrett AR,
    3. Klein R, et al
    . Aortic distensibility and retinal arteriolar narrowing: the Multi-Ethnic Study of Atherosclerosis. Hypertension 2007;50:617–622pmid:17698721
    OpenUrlAbstract/FREE Full Text
  94. ↵
    1. Mitchell GF,
    2. van Buchem MA,
    3. Sigurdsson S, et al
    . Arterial stiffness, pressure and flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility--Reykjavik study. Brain 2011;134:3398–3407pmid:22075523
    OpenUrlCrossRefPubMedWeb of Science
  95. ↵
    1. van Sloten TT,
    2. Czernichow S,
    3. Houben AJ, et al
    . Association between arterial stiffness and skin microvascular function: The SUVIMAX2 Study and The Maastricht Study. Am J Hypertens 2015;28:868–876pmid:25523296
    OpenUrlCrossRefPubMed
  96. ↵
    1. Scalia R
    . The microcirculation in adipose tissue inflammation. Rev Endocr Metab Disord 2013;14:69–76pmid:23378133
    OpenUrlCrossRefPubMed
  97. ↵
    1. Robciuc MR,
    2. Kivelä R,
    3. Williams IM, et al
    . VEGFB/VEGFR1-induced expansion of adipose vasculature counteracts obesity and related metabolic complications. Cell Metab 2016;23:712–724pmid:27076080
    OpenUrlCrossRefPubMed
  98. ↵
    1. Singhal A,
    2. Lucas A
    . Early origins of cardiovascular disease: is there a unifying hypothesis? Lancet 2004;363:1642–1645pmid:15145640
    OpenUrlCrossRefPubMedWeb of Science
  99. ↵
    1. Serné EH,
    2. Stehouwer CDA,
    3. ter Maaten JC,
    4. ter Wee PM,
    5. Donker AJM,
    6. Gans ROB
    . Birth weight relates to blood pressure and microvascular function in normal subjects. J Hypertens 2000;18:1421–1427pmid:11057429
    OpenUrlCrossRefPubMedWeb of Science
  100. ↵
    1. IJzerman RG,
    2. van Weissenbruch MM,
    3. Voordouw JJ, et al
    . The association between birth weight and capillary recruitment is independent of blood pressure and insulin sensitivity: a study in prepubertal children. J Hypertens 2002;20:1957–1963pmid:12359973
    OpenUrlCrossRefPubMedWeb of Science
  101. ↵
    1. Touwslager RNH,
    2. Houben AJHM,
    3. Gielen M, et al
    . Endothelial vasodilatation in newborns is related to body size and maternal hypertension. J Hypertens 2012;30:124–131pmid:22045125
    OpenUrlCrossRefPubMed
  102. ↵
    1. Touwslager RNH,
    2. Gerver WJM,
    3. Tan FES, et al
    . Influence of growth during infancy on endothelium-dependent vasodilatation at the age of 6 months. Hypertension 2012;60:1294–1300pmid:23045464
    OpenUrlAbstract/FREE Full Text
  103. ↵
    1. Eringa EC,
    2. Serné EH,
    3. Meijer RI, et al
    . Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes. Rev Endocr Metab Disord 2013;14:39–48pmid:23417760
    OpenUrlCrossRefPubMed
  104. ↵
    1. Joris PJ,
    2. Plat J,
    3. Kusters YH, et al
    . Diet-induced weight loss improves not only cardiometabolic risk markers but also markers of vascular function: a randomized controlled trial in abdominally obese men. Am J Clin Nutr 2017;105:23–31pmid:27881395
    OpenUrlAbstract/FREE Full Text
  105. ↵
    1. Karatzi K,
    2. Protogerou A,
    3. Kesse-Guyot E, et al
    . Associations between dietary patterns and skin microcirculation in healthy subjects. Arterioscler Thromb Vasc Biol 2014;34:463–469pmid:24357061
    OpenUrlAbstract/FREE Full Text
  106. ↵
    1. Look AHEAD Research Group
    . Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2014;2:801–809pmid:25127483
    OpenUrlCrossRefPubMed
  107. ↵
    1. Rubin RR,
    2. Wadden TA,
    3. Bahnson JL, et al.; Look AHEAD Research Group
    . Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care 2014;37:1544–1553pmid:24855155
    OpenUrlAbstract/FREE Full Text
  108. ↵
    1. Espeland MA,
    2. Erickson K,
    3. Neiberg RH, et al.; Action for Health in Diabetes Brain Magnetic Resonance Imaging (Look AHEAD Brain) Ancillary Study Research Group
    . Brain and white matter hyperintensity volumes after 10 years of random assignment to lifestyle intervention. Diabetes Care 2016;39:764–771pmid:27208378
    OpenUrlAbstract/FREE Full Text
  109. ↵
    1. Rapp SR,
    2. Luchsinger JA,
    3. Baker LD, et al.; Look AHEAD Research Group
    . Effect of a long-term intensive lifestyle intervention on cognitive function: Action for Health in Diabetes Study. J Am Geriatr Soc 2017;65:966–972pmid:28067945
    OpenUrlPubMed
  110. ↵
    1. Jonk AM,
    2. Houben AJHM,
    3. Schaper NC, et al
    . Angiotensin II enhances insulin-stimulated whole-body glucose disposal but impairs insulin-induced capillary recruitment in healthy volunteers. J Clin Endocrinol Metab 2010;95:3901–3908pmid:20501681
    OpenUrlCrossRefPubMedWeb of Science
  111. ↵
    1. Jonk AM,
    2. Houben AJ,
    3. Schaper NC, et al
    . Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals. Microvasc Res 2011;82:77–83pmid:21514308
    OpenUrlCrossRefPubMed
  112. ↵
    1. Sauder MA,
    2. Liu J,
    3. Jahn LA,
    4. Fowler DE,
    5. Chai W,
    6. Liu Z
    . Candesartan acutely recruits skeletal and cardiac muscle microvasculature in healthy humans. J Clin Endocrinol Metab 2012;97:E1208–E1212pmid:22508711
    OpenUrlCrossRefPubMed
  113. ↵
    1. Elliott WJ,
    2. Meyer PM
    . Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201–207pmid:17240286
    OpenUrlCrossRefPubMedWeb of Science
  114. ↵
    1. Garg R,
    2. Rao AD,
    3. Baimas-George M, et al
    . Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 2015;64:236–242pmid:25125488
    OpenUrlAbstract/FREE Full Text
  115. ↵
    1. Carlsson LMS,
    2. Sjöholm K,
    3. Karlsson C, et al
    . Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol 2017;5:271–279pmid:28237791
    OpenUrlPubMed
  116. ↵
    1. Nigro C,
    2. Raciti GA,
    3. Leone A, et al
    . Methylglyoxal impairs endothelial insulin sensitivity both in vitro and in vivo. Diabetologia 2014;57:1485–1494pmid:24759959
    OpenUrlCrossRefPubMed
  117. ↵
    1. Xue M,
    2. Weickert MO,
    3. Qureshi S, et al
    . Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation. Diabetes 2016;65:2282–2294pmid:27207552
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Maessen DE,
    2. Brouwers O,
    3. Gaens KH, et al
    . Delayed intervention with pyridoxamine improves metabolic function and prevents adipose tissue inflammation and insulin resistance in high-fat diet-induced obese mice. Diabetes 2016;65:956–966pmid:26718500
    OpenUrlAbstract/FREE Full Text
  119. ↵
    1. de Jager J,
    2. Kooy A,
    3. Schalkwijk C, et al
    . Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med 2014;275:59–70pmid:23981104
    OpenUrlCrossRefPubMed
  120. ↵
    1. Koska J,
    2. Sands M,
    3. Burciu C, et al
    . Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes 2015;64:2624–2635pmid:25720388
    OpenUrlAbstract/FREE Full Text
  121. ↵
    1. Lovshin J,
    2. Cherney D
    . GLP-1R agonists and endothelial dysfunction: more than just glucose lowering? Diabetes 2015;64:2319–2321pmid:26106189
    OpenUrlFREE Full Text
  122. ↵
    1. Chai W,
    2. Dong Z,
    3. Wang N, et al
    . Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012;61:888–896pmid:22357961
    OpenUrlAbstract/FREE Full Text
  123. ↵
    1. Subaran SC,
    2. Sauder MA,
    3. Chai W, et al
    . GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond) 2014;127:163–170pmid:24552454
    OpenUrlCrossRefPubMed
  124. ↵
    1. Mann JFE,
    2. Ørsted DD,
    3. Brown-Frandsen K, et al.; LEADER Steering Committee and Investigators
    . Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377:839–848pmid:28854085
    OpenUrlCrossRefPubMed
  125. ↵
    1. Simó R,
    2. Hernández C
    . GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes 2017;66:1453–1460pmid:28533296
    OpenUrlAbstract/FREE Full Text
  126. ↵
    1. Wanner C,
    2. Inzucchi SE,
    3. Lachin JM, et al.; EMPA-REG OUTCOME Investigators
    . Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–334pmid:27299675
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Advertisement
Diabetes: 67 (9)

In this Issue

September 2018, 67(9)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
Citation Tools
Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences
Coen D.A. Stehouwer
Diabetes Sep 2018, 67 (9) 1729-1741; DOI: 10.2337/dbi17-0044

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences
Coen D.A. Stehouwer
Diabetes Sep 2018, 67 (9) 1729-1741; DOI: 10.2337/dbi17-0044
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Microvascular Function
    • Hyperglycemia Causes Mvd: Novel Aspects
    • Mvd Contributes To Hyperglycemia
    • Obesity Is An Important Driver Of Mvd
    • Early-Life Exposures And Mvd
    • Interventions To Improve Microvascular Function
    • Conclusions
    • Article Information
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
  • Type 1 Diabetes in STAT Protein Family Mutations: Regulating the Th17/Treg Equilibrium and Beyond
  • Mitochondrial Stability in Diabetic Retinopathy: Lessons Learned From Epigenetics
Show more Perspectives in Diabetes

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • For Advertisers
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org
Advertisement

© 2019 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.